人体肝脏中二元酸盐酸酶的二元酸盐示例是复合平衡和全调节的联合作用
Tyler A Martin1, Aron W Fenton2
1Department of Biochemistry and Molecular Biology, The University of Kansas Medical Center, MS 3030, 3901 Rainbow Boulevard, Kansas City, KS, 66160, USA.
Scientific reports
|June 29, 2023
概括
人类肝脏酸激酶 (hLPYK) 的全调节是复杂的,双价影响激活剂,抑制剂和酸 (PEP) 等基质之间的相互作用. 这些依赖于阴离子的效应改变了酶活性和全结合.
科学领域:
- 生物化学 生化学
- 酶学 是一种酶学.
- 所有的其他法规.
背景情况:
- 体调节剂对蛋白质功能的影响取决于其他结合的连接体.
- 人体肝炎酸酶 (hLPYK) 是一种关键的糖解酶.
- 了解hLPYK调节对于代谢研究至关重要.
研究的目的:
- 为了研究各种双价离子对hLPYK全调节的影响.
- 分析阴离子类型和度如何影响连接体之间的相互作用.
- 探索观测到的合复杂性背后的机制.
主要方法:
- 评估了hLPYK与果糖-1,6-双酸盐 (激活剂) 和氨酸 (抑制剂) 的活性,在存在各种双价 (Mg2+, Mn2+, Ni2+, Co2+, Zn2+, Cd2+, V2+, Pb2+, Fe2+, Cu2+) 的情况下.
- 评估了阴离子类型和度对基质 (酸酸 - PEP) 亲和力的影响.
- 观察到连接体和PEP之间的全性合.
主要成果:
- 二元酸盐显著调节了果糖-1,6-双酸盐和PEP之间以及氨酸和PEP之间的全性合.
- 体相互作用依赖于双价离子的类型和度.
- 观察到的"基质抑制"可能源于hLPYK多重体中的跨位点性调节.
结论:
- 双酸盐在调节hLPYK的全调节方面发挥着至关重要的作用.
- 复杂的配体相互作用,包括基质抑制,可以通过多位点的全效应来解释.
- 对这些复杂的监管机制进行进一步调查是有必要的.
相关概念视频
Allosteric Regulation
58.3K
Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
58.3K
Allosteric Proteins-ATCase
5.8K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.8K
EDTA: Conditional Formation Constant
976
Each EDTA molecule has six binding sites: four carboxyl groups and two amino groups. The fully protonated form of EDTA is represented as H6Y2+. However, it can exist in different forms, H5Y+, H4Y, H3Y−, H2Y2−, and HY3−, depending on the pH of the solution. In very basic solutions with pH > 10.17, the fully deprotonated form, Y4−, is the predominant species that readily complexes with metal ions in a 1:1 ratio.
For the equilibrium reaction of the metal with the...
For the equilibrium reaction of the metal with the...
976
Regulation of Metabolism
9.5K
Cellular needs and conditions vary from cell to cell and change within individual cells over time. For example, the required enzymes and energetic demands of stomach cells are different from those of fat storage cells, skin cells, blood cells, and nerve cells. Furthermore, a digestive cell works much harder to process and break down nutrients during the time that closely follows a meal compared with many hours after a meal. As these cellular demands and conditions vary, so do the amounts and...
9.5K
Ligand Binding and Linkage
4.8K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.8K
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
61
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
61


